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Abstract. TP53-regulated inhibitor of apoptosis 1 (TRIAP1) is 
a novel apoptosis inhibitor that binds HSP70 in the cytoplasm 
and blocks the formation of the apoptosome and caspase-9 
activation. TRIAP1 has been shown to be upregulated in 
many types of cancers; however, its role remains elusive. We 
determined the TRIAP1 mRNA levels in a panel of human 
tissues and found its expression to be ubiquitous. Normal 
breast, as well as non-tumorigenic breast cells, exhibited 
lower TRIAP1 mRNA levels than breast cancer cells or their 
drug-resistant derivatives. TRIAP1 is a small, evolutionarily 
conserved protein that is 76 amino acids long. We found that 
yeast cells, in which the TRIAP1 homologue was knocked out, 
had increased sensitivity to doxorubicin. Equally, RNA inter-
ference in breast cancer drug-resistant cells demonstrated that 
downregulation of TRIAP1 impaired cell growth in the pres-
ence of doxorubicin. As expected, caspase-9 activation was 
diminished after overexpression of TRIAP1 in drug-resistant 
cells. Importantly, stable transfections of a TRIAP1 expression 
plasmid in CAL51 cells led to a marked increase in the number 
of doxorubicin-resistant clones, that was abolished when cells 
expressed hairpins targeting TRIAP1. In addition, we showed 
that TRIAP1 expression was also triggered by estrogen 
deprivation in MCF-7 cells. Although both polyclonal and 
monoclonal antibodies generated for the present study failed 
to robustly detect TRIAP1, we demonstrated that TRIAP1 
represents a novel marker for drug resistance in breast cancer 
cells and it may be used in the stratification of breast cancer 
patients once a suitable antibody has been developed. Equally, 
these studies open potential drug development strategies for 
blocking TRIAP1 activity and avoiding drug resistance.
Introduction
One of the many mechanisms by which cancer cells acquire 
drug resistance is by apoptosis evasion (1,2). Antineoplastic 
agents activate the apoptotic intrinsic pathway which 
results in the permeabilization of the outer mitochondrial 
membrane. The subsequent release of cytochrome c and other 
pro-apoptotic molecules leads to the formation of a large 
protein complex, the apoptosome, containing cytochrome c, 
apoptotic protease activating factor 1 (Apaf-1) and caspase-9. 
Regulation of these processes occurs through the activity of 
members of the BCL-2 family of proteins (3). Upregulation 
of anti-apoptotic proteins, such as BCL-2, BCL-XL, and 
members of the inhibitor of apoptosis (IAP) family, and 
inactivating mutations in pro-apoptotic proteins Bax and 
Bak, or p53 have been described in both the development of 
cancer and drug resistance (2,4). Among several therapeutic 
strategies, the restoration of p53-mediated apoptosis in cancer 
cells has been sought for some time, so far without a clinical 
application (5,6). Therefore, targeting inhibitors of apoptosis 
offer another opportunity for drug development (7).
TP53-regulated inhibitor of apoptosis 1 (TRIAP1; alias 
p53CSV, p53-inducible cell-survival factor) is a small, evolu-
tionarily conserved protein that is 76 amino acids long and 
contains a twin Cx9C motif. Its expression is induced by p53 
following low levels of genotoxic stress (8). In yeast it is located 
in the mitochondrial intermembrane space where it can interact 
with both Ups1 and Ups2, protecting them against proteolysis 
and regulating cardiolipin and phosphatidylethanolamine 
levels within mitochondria (9). In its extramitochondrial role, 
TRIAP1 modulates apoptotic pathways through interaction 
with HSP70, inhibition of the interaction of cytochrome c with 
Apaf-1 and activation of caspase-9, to inhibit apoptosis and 
permit DNA damage repair (8,10). Despite its name, TRIAP1 
Apoptosis inhibitor TRIAP1 is a novel effector of drug resistance
CAROLINE ADAMS1*,  GIULIA CAzzANELLI1*,  SABEENA RASUL1,  BEN HITCHINSON1,  YUNHUI HU1,2,  
R. CHARLES COOMBES1,  SELINA RAGUz3  and  ERNESTO YAGüE1*
1Cancer Research Centre, Division of Cancer, Imperial College London, Hammersmith Hospital Campus, 
London W12 0NN, UK; 2Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment 
and Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300020, P.R. China; 
3Institute of Clinical Sciences, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK
Received February 20, 2015;  Accepted March 23, 2015
DOI: 10.3892/or.2015.3988
Correspondence to: Dr Ernesto Yagüe, Cancer Research Centre, 
Division of Cancer, Imperial College London, Hammersmith Hospital 
Campus, Du Cane Road, London W12 0NN, UK
E-mail: ernesto.yague@imperial.ac.uk
*Contributed equally
Abbreviations: Apaf-1, apoptotic protease activating factor 1; 
DMEM, Dulbecco's modified Eagle's medium; DMEM-PR, DMEM 
lacking phenol red; DSS, dextran-coated charcoal-stripped FCS; FCS, 
foetal calf serum; HMECs, human primary mammary epithelial cells; 
IAP, inhibitor of apoptosis; TRIAP1, TP53-regulated inhibitor of 
apoptosis 1
Key words: inhibitors of apoptosis, drug resistance, doxorubicin, 
caspases, estrogen, tamoxifen
ADAMS et al:  TRIAP1 IS AN EFFECTOR OF DRUG RESISTANCE416
does not share any similarity with XIAP, c-IAP, survivin or 
other members of the IAP family (11). TRIAP1 is upregulated 
in myelomas with unfavorable prognosis (12) and TRIAP1 
mRNA has been found in all breast cancer cell lines tested (13). 
However, the role of TRIAP1 in breast or other solid tumors 
has been poorly addressed.
Breast cancer is one of the most common tumors affecting 
women, and chemotherapy, endocrine therapy and radio-
therapy regimens are part of the present mainstream treatment. 
Even those cancers that initially respond well to treatment may 
become resistant and give rise to secondary tumors, normally 
with fatal consequences (14). Thus, it is crucial to be able 
to predict which patients will respond to therapy in order to 
design the best clinical strategy available and to develop drugs 
for the treatment of resistance (15).
Here we describe the upregulation of TRIAP1 in 
drug-resistant breast cancer cells. Experimental modulation 
of TRIAP1 in breast cancer cells, either by overexpression 
or downregulation by RNA interference, changed cellular 
sensitivity to doxorubicin, thus confirming TRIAP1 as a novel 
effector of drug resistance.
Materials and methods
Cell culture, transduction and transfection. The breast cancer 
cell lines CAL51 (German Resource Centre for Biological 
Material, DSMz, Braunschweig, Germany) and MCF7 
(European Collection of Cell Cultures, Health Protection 
Agency, UK) were grown in low glucose (1 g/l) Dulbecco's 
modified Eagle's medium (DMEM)-GlutaMax (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% foetal calf serum 
(FCS). Drug-resistant derivatives CALDOX, MCFDOX and 
MLET5 have been previously described (16-18). RNA from 
MDA-MB-231, T47D, zR75 and 226-L-U19 cells (19) was 
a generous gift from Y. zhou. Human primary mammary 
epithelial cells (HMECs) were purchased from Invitrogen 
and immortalized by expression of the catalytic subunit of 
human telomerase as previously described (20) to generate 
HMEC-TERT cells. HMECs were grown on Mammary 
Epithelial Cell Growth Medium (Invitrogen). GP2-293 
pantropic retroviral packaging (Clontech Laboratories, 
Mountain View, CA, USA) and HEK293T cells (American 
Type Culture Collection, LGC Standards, Teddington, UK) 
were maintained in DMEM supplemented with 4.5 g/l glucose, 
10% FCS and 4 mM L-glutamine (Invitrogen). For culturing 
in estrogen-free conditions, MCF-7 cells were cultured in 
DMEM lacking phenol red (DMEM-PR; Gibco-BRL, UK), 
supplemented with 10% dextran-coated charcoal-stripped 
FCS (DSS; First Link Ltd., UK). MLET5 cells were routinely 
cultured in DMEM-PR, containing 10% DSS. All cells were 
routinely tested for the presence of mycoplasma using the 
Lonza MycoAlert kit (Basel, Switzerland).
DNA procedures. A human TRIAP1 cDNA clone with a 
C-terminal GFP tag cloned into pCMV6-AC-GFP was 
purchased from Origene and used for transient transfections. 
For stable transfections, the genomic region encompassing 
TRIAP1 (first and second exons including both 5'- and 3'-UTRs 
as well as the single intervening sequence) was amplified from 
genomic DNA isolated from IMR-90 fibroblasts by PCR using 
Platinum® Taq DNA Polymerase High Fidelity (Invitrogen) 
with primers OLEY335 and OLEY336 (Table Ι). The ampli-
fied 2.6-kbp fragment was initially cloned into pCRII-TOPO 
(Invitrogen) and the TRIAP1 open reading frame verified 
by sequencing. Then, the genomic TRIAP1 fragment was 
liberated by digestion with BamHI and EcoRI and cloned 
into the BamHI- and EcoRI-digested lentiviral vector FUW. 
Retroviral plasmids pGFP-V-RS expressing short hairpins 
targeting TRIAP1 (5'-AGAGATTCCTATTGAAGGACTGG 
AGTTCA-3') and non-targeting scrambled (TR30013) were 
from Origene.
Viral transduction. Viral transductions were essentially as 
previously described (16). Briefly, retroviral transfections 
were performed using 20 µg retroviral plasmid, 2 µg pVSV-G 
(Clontech Laboratories) and 55 µg Polyethylenimine (MW 
25,000) (Polysciences, Warrington, PA, USA) prior to co-trans-
fection into the GP2-293 pantropic retroviral packaging cells. 
Lentiviral transfections were performed using 20 µg lentiviral 
plasmid, 2 µg pVSV-G, 8 µg pPAX2 (Addgene, Cambridge, 
MA, USA) and 75 µg Polyethylenimine (MW 25,000) (Sigma-
Aldrich, St. Louis, MO, USA) prior to co-transfection into the 
HEK293T cells. Viral supernatants were collected 24-48 h 
after transfections, filtered through 0.45-µm cellulose acetate 
filters and supplemented with 8 µg/ml Polybrene (Sigma-
Aldrich) prior to adding to recipient cells. Puromycin (1 µg/
ml; Sigma-Aldrich) was added 96 h after the first infection to 
recipient cells for selection of stable transgene expression.
Transient transfections. Cells (1x105 in 6-well plates) 
were transfected with a final concentration of 40 nM 
ON-TARGETplus SMARTpool TRIAP1 siRNA oligonucle-
otides (Thermo Scientific) using HiPerFect (Qiagen, UK) 
following the manufacturer's instructions. EGFP siRNA 
(Ambion, UK) was used as a negative control (21). A sulpho-
rhodamine B (Sigma-Aldrich) assay (22) was used to screen 
for drug cytotoxicity as previously described (19). For transient 
overexpression, cells (1x104) were seeded in 96-well plates 
and transfected with FuGENE HD (Promega, Madison, WI, 
USA) using 2 µg DNA as recommended by the manufacturer. 
Then cells were treated for 24 h with 0.4 µM doxorubicin, 
and caspase-9 activity was determined using a Caspase-Glo 9 
assay (Promega) following the manufacturer's instructions and 
normalized to cell density obtained after sulphorhodamine B 
staining.
Gene expression analysis. Total RNA (isolated using 
RNAzol B; Biogenesis, Poole, UK) was reverse transcribed 
with RNase H+ MMLV Reverse Transcriptase (iScript cDNA 
Synthesis kit; Bio-Rad) and real-time quantitative PCR was 
performed using SYBR-Green (Bioline Reagents, London, 
UK) and gene specific primers (Table I) on an ABI Prism 7700 
Detection system (PerkinElmer Life Sciences, Waltham, 
MA, USA). PCR conditions included an initial step at 95˚C 
for 10 min followed by 40 cycles of 95˚C for 30 sec, 60˚C for 
30 sec and 72˚C for 30 sec. A comparative threshold cycle 
was used to determine the relative gene expression as previ-
ously described (23). TFF1 expression was performed using 
TaqMan Gene Expression assay Hs00907239_m1 (Invitrogen) 
following the manufacturer's instructions.
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Yeast procedures. Wild-type Saccharomyces cerevisiae 
BY4743 (MATa/α his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/ 
MET15 lys2Δ0/LYS2 ura3Δ0/ura3Δ0) and Mdm35 knockout 
strain were purchased from Open Biosystems. Screening for 
drug toxicity was performed in YPD plates with doxorubicin 
after 3 days of growth.
Drug resistance clonogenic assay. Cells were seeded, at least 
in duplicate, at a density of 1-5x105 cells in 25-cm2 culture 
flasks and exposed to a single dose of doxorubicin for 24 h. 
Cells were kept in culture for 2-4 weeks with drug-free 
medium changes every week. Drug-resistant clones were fixed 
with 4% paraformaldehyde and stained with 0.2% crystal 
violet. Crystal violet retained in the cells was quantified by 
solubilization with 33% acetic acid and measured at OD592 nm.
Statistical analysis. Statistical evaluations were performed 
using the Student's t-test for paired data, and data were consid-
ered significant at a P-value <0.05.
Results
TRIAP1 is ubiquitously expressed in normal human tissues 
and upregulated in breast cancer cells. We initially tested 
TRIAP1 expression in a panel of RNAs from normal human 
tissues (24) and found it ubiquitously expressed (Fig. 1A). 
Although there was a lack of tissue specificity, bone marrow, 
heart and kidney showed very low expression, whereas 
brain, placenta and testis showed high expression, with that 
from skeletal muscle being the highest. Normal breast tissue 
expressed TRIAP1 mRNA at intermediate levels (Fig. 1A). 
Next we tested TRIAP1 mRNA expression in four breast 
cancer cell lines (CAL51, MDA-MB-231, T47D and zR75) 
and in two immortal, but non-tumorigenic, breast cell lines 
(HMEC-TERT and 226-L-U19). An ~2-fold upregulation was 
found in the cancerous cell lines, indicating that malignant 
transformation of breast epithelial cells is, at least in vitro, 
associated with TRIAP1 upregulation (Fig. 1B).
A polyclonal antibody raised to the synthetic peptide 
CVQKAIKEKEIPIEGLEF (amino acids 47-64) as well 
as three monoclonal antibodies raised to the epitopes 
HGKEKPENSS (amino acids 67-76), IKEKEIPIEG (amino 
acids 52-61) and FAEKFLKGDS (amino acids 23-32), all 
failed to robustly detect TRIAP1 as a band at ~10 kDa (data 
not shown). Equally, a few commercial antibodies were tested 
and failed in the same way (data not shown). Thus, TRIAP1 
expression analyses throughout the present study were 
performed exclusively at the mRNA level.
TRIAP1 is upregulated in drug-resistant breast cancer cell 
lines. TRIAP1 upregulation following genotoxic stress has 
been exclusively demonstrated in a colon cancer cell line (8). 
We confirmed that CAL51 breast cancer cells exhibited upreg-
ulation of TRIAP1 mRNA expression after 24 h of doxorubicin 
treatment at low to moderate doses (up to 0.4 µM). Higher 
doses (2-5 µM) repressed TRIAP1 expression (Fig. 1C). Then 
we examined whether TRIAP1 was associated with a drug-
resistance phenotype. For this, we tested TRIAP1 mRNA 
expression in two doxorubicin-resistant breast cancer cell 
lines derived from CAL51 (16) and MCF7 (17) cells, and in a 
third cell line derived from MCF7 cells after estrogen depri-
vation, which are resistant to tamoxifen and etoposide (18). 
Doxorubicin and etoposide are two topoisomerase II inhibitors 
producing genotoxic stress, ultimately leading to apoptosis, 
which form part of many chemotherapeutic cancer regimes. 
TRIAP1 mRNA was upregulated in these three drug-resistant 
cell types between 3- and 8-fold (Fig. 1D).
TRIAP1 is an effector of drug resistance. In order to deter-
mine whether TRIAP1 is an effector of drug resistance, we 
tested cell susceptibility to doxorubicin after experimental 
modulation of TRIAP1 expression. Comparison of TRIAP1 
protein sequences revealed a striking conservation across 
kingdoms (Fig. 2A), albeit not at the C-terminus, indicating 
that this protein must perform a fundamental role in cellular 
physiology. The TRIAP1 homologue in S. cerevisiae, Mdm35, 
shares 33% identity with human TRIAP1. Since yeast cells 
harbour an ancestral programmed cell death machinery that 
shares many key molecules that are part of the apoptotic 
intrinsic pathway in mammalian cells (25), and because 
genetic manipulation of yeast allows the knockout of genes, 
we initially tested our hypothesis in Mdm35 knockout yeast 
cells. Indeed, ΔMdm35 cell growth was greatly inhibited 
by the presence of doxorubicin in the yeast growth medium 
compared to wild-type cell growth (Fig. 2B).
Next, we determined whether experimental downregulation 
of TRIAP1 would have a similar effect in breast cancer cells. 
For this, we transiently transfected siRNAs targeting TRIAP1 
Table I. Oligonucleotides used in this study,
Primer Sequence (5'-3') Use
OLEY335 GGGGGATCCCGACGCGCCTGAGAGTGATGACATCA TRIAP1 genomic amplification
OLEY336 GGGGTCGACTGTGAGGTTTCTGATTGCCATACTG TRIAP1 genomic amplification
OLEY287 AGGATTTCGCAAGTCCAGAA TRIAP1 QPCR
OLEY288 GCTGATTCCACCCAAGTAT TRIAP1 QPCR
OLEY373 TCACCGCCCTACACATCAAACT RPS14 QPCR
OLEY374 CTGCGAGTGCTGTCAGAGG RPS14 QPCR
OLEY375 AGGGTTATGTGGTCCGAATCA RPS6 QPCR
OLEY376 TGCCCCTTACTCAGTAGCAGG RPS6 QPCR
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mRNA in doxorubicin-resistant CALDOX cells and obtained 
~60% downregulation in TRIAP1 mRNA levels (Fig. 3A). 
Transfection of siRNAs targeting EGFP mRNA, which is not 
expressed in these cells, was used as a negative control. This 
transient decrease in TRIAP1 mRNA levels was sufficient to 
inhibit the proliferation of cells in the presence of doxorubicin 
compared to the slight decrease in proliferation obtained with 
the negative control (Fig. 3B).
As TRIAP1 blocks the formation of the apoptosome 
and activation of caspase-9 (8), we next ascertained whether 
caspase-9 activity would be reduced by TRIAP1 in breast 
cancer cells. To do this, we transiently overexpressed TRIAP1 
in CAL51 cells (Fig. 3C) and treated them with 0.4 µM doxo-
rubicin for 24 h. As expected, the control cells transfected 
with an empty vector exhibited increased caspase-9 activity, 
and this increase was reduced in the cells overexpressing 
TRIAP1 (Fig. 3D).
Although experiments performed with transient transfec-
tions are informative to assess the short-term susceptibility to 
cytotoxic drugs, the generation of drug resistance is a slower 
process, often taking several weeks in vitro, and required a 
different approach. We generated CAL51 derivative cells that 
had either permanently downregulated TRIAP1 by stable 
expression of hairpins targeting TRIAP1 mRNA (shTRIAP) 
or permanently upregulated TRIAP1. CAL-shTRIAP cells 
showed decreased levels of TRIAP1 mRNA by ~60% (Fig. 4A). 
In addition, we managed to reproduce the slight increase in 
TRIAP1 mRNA expression found in drug-resistant CALDOX 
cells by using low multiplicity of infection of the lentivirus 
used for TRIAP1 overexpression (Fig. 4A). Thus, although 
these experimental changes in TRIAP1 expression after 
stable gene expression were modest, they reflect very accu-
rately the difference found between naïve and drug-resistant 
cells (Fig. 1D). Next we performed clonogenic assays after 
doxorubicin treatment. For this, doxorubicin was added to 
cell cultures and the emergence of doxorubicin-resistant 
clones was monitored over a period of 2-4 weeks. Stable 
experimental overexpression of TRIAP1 led to an increase in 
doxorubicin-resistant clones, and, conversely, downregulation 
of TRIAP1 led to fewer drug-resistant clones than the control 
cells (Fig. 4B and C).
TRIAP1 is upregulated by lack of estrogen. As tamoxifen-resis-
tant cells have elevated levels of TRIAP1 mRNA (Fig. 1D), 
Figure 1. TRIAP1 is a ubiquitously expressed gene which is upregulated in transformed mammary epithelial cells, after genotoxic stress, and in drug-resistant 
cells. (A) TRIAP1 mRNA is expressed ubiquitously in normal human tissues. A panel of 21 human tissues was used to analyze TRIAP1 mRNA expression 
by RT-QPCR. Two normalizers, RPS6 and RPS14 were used. (B) TRIAP1 mRNA is upregulated in tumorigenic breast cancer cell lines. A small panel of 
both tumorigenic and non-tumorigenic breast cell lines was used to determine TRIAP1 mRNA expression by RT-QPCR. Data were normalized to RPS6 
expression. (C) TRIAP1 gene expression is upregulated after moderate genotoxic stress. Breast cancer CAL51 cells were treated with doxorubicin for 24 h and 
TRIAP1 mRNA expression was determined by RT-QPCR. Data were normalized to RPS6 mRNA expression. (D) TRIAP1 mRNA expression is upregulated 
in drug-resistant breast cancer cells. TRIAP1 mRNA expression was determined by RT-QPCR and normalized to RPS6. Doxorubicin-resistant CALDOX and 
MCFDOX cells were derived from CAL51 and MCF-7, respectively. MLET5 is an estrogen-deprivation resistant derivative from MCF-7 cells with resistance 
to tamoxifen. Data represent the average ± SD of three independent experiments (*P<0.05).
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we investigated whether a link exists between estrogen and 
TRIAP1 expression. We cultured MCF-7 and MLET5 cells for 
3 days in estrogen-deprived medium, re-introduced estrogen 
for 16 h, and then determined TRIAP1 mRNA levels. There 
Figure 2. Knockout of TRIAP1 in yeast leads to increased doxorubicin sensitivity. (A) TRIAP1 is a highly conserved protein. TRIAP1 protein sequences 
(accession numbers indicated on the left) of several organisms (indicated on the right) were aligned using ClustaLW at the European Bioinformatics Institute. 
Identical amino acids are shown in black background and similar ones in grey background. Conserved amino acids with a lesser degree of similarity are 
indicated with an asterisk. (B) Saccharomyces cerevisiae cells with the TRIAP1 homologue Mdm35 knocked out are sensitive to doxorubicin. Yeast cell 
cultures at different dilutions were spotted onto YPD plates with or without doxorubicin and left to grow for 3 days.
Figure 3. Transient modulation of TRIAP1 expression affects the sensitivity of breast cancer cells to doxorubicin. (A and B) Transient downregulation of 
TRIAP1 increases drug sensitivity. (A) Doxorubicin-resistant CALDOX cells were transiently transfected with siRNAs targeting either TRIAP1 mRNA or 
EGFP (used as negative control), and TRIAP1 mRNA expression was determined by RT-QPCR after normalization to RPS6. (B) After siRNA transfection, 
cell growth in the presence of 0.4 µM doxorubicin was monitored (sulforhodamine B staining) for up to 4 days. (C and D) Transient overexpression of 
TRIAP1 blocks caspase-9 activation. Breast cancer CAL51 cells were transiently transfected with a TRIAP1 expression vector. (C) TRIAP1 mRNA levels were 
determined as above and (D) caspase-9 activation was determined 24 h after adding 0.4 µM doxorubicin. Caspase-9 levels were normalized to cell density by 
sulforhodamine B staining. Data represent the average ± SD of three independent experiments (*P<0.05).
ADAMS et al:  TRIAP1 IS AN EFFECTOR OF DRUG RESISTANCE420
was no upregulation of TRIAP1 in any cell type; in fact, 
MCF-7 cells treated with 10 nM estrogen showed a slight 
decrease in TRIAP1 expression (Fig. 5A). As expected, the 
estrogen-responsive gene TFF1 (26) was upregulated in both 
cell lines (Fig. 5A). This indicates that TRIAP1 is not an 
estrogen-responsive gene. Importantly, when MCF-7 cells 
were cultured in the absence of estrogen, TRIAP1 expres-
sion was upregulated (Fig. 5B). Moreover, the addition of 
tamoxifen, which blocks estrogen receptor activation, led to 
a small but significant upregulation of TRIAP1 mRNA in the 
MCF-7 cells, but not, as expected, in the tamoxifen resistant 
MLET5 cells (Fig. 5C).
Overall, these results establish TRIAP1 as a novel effector 
of drug resistance in breast cancer cells.
Discussion
One of the many mechanisms by which cancer cells develop 
resistance to therapeutic intervention is by apoptosis evasion. 
This is not surprising since the apoptotic machine is complex, 
with multiple layers of regulation (1,2). The IAP gene family 
encodes a group of structurally-related proteins sharing a BIR 
domain, such as XIAP or survivin, which can be upregulated 
in breast cancer (27,28). However, other inhibitors of apoptosis 
do not share structural similarities with members of the IAP 
family. One such protein, TRIAP1, is a small, 76-amino acid 
protein in humans that binds to HSP70 and inhibits the formation 
of the apoptosome. Apoptosis evasion is one of the hallmarks 
of cancer (29), and is thus not surprising to find TRIAP1 
mRNA upregulated in a variety of malignancies (30-32) and 
in breast cancer cell lines, but not in TERT-immortalized 
primary mammary epithelial cells or in cells transformed but 
not yet fully tumorigenic (Fig. 1B). Although the mechanisms 
upregulating TRIAP1 during tumorigenesis are not known, a 
low to moderate amount of several genotoxic agents triggers 
its expression via p53 activation (8). Importantly we also found 
that estrogen deprivation upregulated TRIAP1. Estrogen depri-
vation reduces p53 activity (33,34), and in normal mammary 
epithelial cells tamoxifen activates p53 (35), although not 
in MCF-7 cells (36). Thus, the upregulation of TRIAP1 in 
these cases is very likely to be p53-independent. Our data 
clearly demonstrated that TRIAP1 is a novel effector of drug 
resistance. Its experimental overexpression confers cells the 
capacity to develop doxorubicin-resistant derivatives, whereas 
its downregulation by RNA interference generates cells more 
susceptible to the cytotoxic effects of the drug.
Figure 4. TRIAP1 is an effector of drug resistance. (A) CAL51 cells were stably transfected with a TRIAP1 expression construct (CAL-TRIAP) or empty vector 
as control (CAL-ev). Stably transfected cells with either downregulated or upregulated TRIAP1 were generated by retroviral (small hairpins) or lentiviral 
transfection of CAL51 cells. TRIAP1 mRNA expression was determined by RT-QPCR after normalizing to RPS6. (B) Cells (10,000/25 cm2) overexpressing 
TRIAP1 (CAL-TRIAP) (or empty vector control cells, CAL-ev) were treated with 50 nM doxorubicin/ml and left in culture for 2 weeks (upper panel). Cells 
(50,000/25 cm2) expressing a hairpin targeting TRIAP1 mRNA (CAL-shTRIAP) (or scrambled control cells, CAL-shCONTROL) were treated with 50 nM 
doxorubicin/ml and left in culture for 4 weeks (lower panel). Drug-resistant clones were stained with crystal violet. (C) Crystal violet was solubilized and 
optical density was determined at 592 nm. Numerical data represent the average ± SD of 3 experiments (*P<0.05). Images show a representative of at least 
3 replicates.
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Due to its ubiquitous tissue expression in humans and 
extremely high conservation throughout evolution it is likely 
that TRIAP1 has an important function in eukaryotic cells. 
Research on yeast indicates that TRIAP1 (Mdm35) normally 
resides in the mitochondrial intermembrane space where it 
interacts with Usp1 and Usp2 (PRELI1 and PRELI2 in humans) 
to regulate the synthesis of cardiolipin and phosphatidylethanol-
amine, respectively (9). Although TRIAP1/PRELI complexes 
(Mdm35/Usp homologues in yeast) have been shown to prevent 
apoptosis by mediating intramitochondrial transport of phos-
phatidic acid in HeLa cells (37), it is tempting to speculate that 
the upregulation of TRIAP1 expression following moderate 
genotoxic stress (Fig. 1C), or that found in drug-resistant 
cells (Fig. 1D), helps to maintain the balance towards apoptosis 
inhibition by blocking apoptosome formation and caspase-9 
inactivation (8). However, after stronger genotoxic stress, which 
probably leads to irreparable DNA damage, there is no activa-
tion of TRIAP1 expression. A large escape of cytochrome c 
from the mitochondria would be enough to change the balance 
towards apoptosome formation and the background levels of 
TRIAP1 protein would not be enough to block the interaction 
cytochrome c-Apaf1-caspase-9 (38). In addition, it is not clear 
whether, in addition to cytochrome c, TRIAP1 or TRIAP1/
PRELID complexes can also escape from the intermembrane 
space following stress to interact with HSP70. Nonetheless, 
yeast data as well as those presented here indicate a dual role 
for TRIAP1 in mitochondrial lipid biosynthesis and drug resis-
tance. This may offer a potential drug development strategy for 
the synthesis of compounds blocking TRIAP1 activity.
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